查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701653

人类乳突病毒 (HPV) 检测市场：全球产业分析、规模、份额、成长、趋势和预测（2025-2032 年）

Human Papillomavirus (HPV) Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 192 Pages | 商品交期: 2-5个工作天内

价格
简介目录

主要发现

  • HPV检测市场规模：14亿美元（2025年）
  • 预计市值：28.163亿美元（2032年）
  • 全球市场成长率：10.5%（2025年至2032年的复合年增长率）

HPV检测市场 - 报告范围

HPV检测是子宫颈癌筛检和预防计画的重要组成部分。这些测试可以检测出与子宫颈癌发展相关的高危险 HPV 株的存在。该市场面向医院、诊断实验室和诊所，并透过 PCR、混合捕获和次世代定序(NGS) 等各种平台提供基于 DNA 和 mRNA 的检测选项。人们对 HPV 与子宫颈癌之间关联的认识不断提高，加上政府提倡定期筛检，极大地推动了市场的成长。早期诊断需求的不断增长、新兴地区医疗基础设施的不断扩大以及 HPV 检测被纳入国家筛检指南，进一步推动了市场扩张。

市场成长动力

全球 HPV 检测市场主要受到全球 HPV 感染率上升和子宫颈癌发生率上升的推动。政府的优惠政策和宣传宣传活动提倡定期筛检和早期发现，从而提高了患者的依从性和筛检率。自采集试剂套件、液基细胞学和高灵敏度分子诊断的发展等技术进步彻底改变了 HPV 检测，提供了更高的准确性和便利性。此外，人们对女性健康的关注度日益提高，尤其是在中低收入国家，这推动了对价格实惠、易于取得的 HPV 筛检工具的需求。公共卫生机构和诊断公司的合作在扩大HPV检测服务方面也发挥了重要作用。

市场限制

儘管市场动能良好，HPV 检测仍面临若干挑战。高昂的检测成本仍然是广泛采用的主要障碍，尤其是在新兴经济体。在农村和服务不足的地区，获得先进诊断工具的机会有限，医疗保健基础设施不发达进一步阻碍了市场渗透。此外，文化障碍、性健康的耻辱感以及某些领域缺乏意识也阻碍了患者参与筛检计画。此外，监管障碍和新诊断技术核准的延迟也给製造商和医疗保健提供者带来了挑战。透过教育、公共卫生投资和创新交付模式解决这些问题对于市场的持续成长至关重要。

市场机会

HPV 检测市场提供了巨大的机会，尤其是随着家用检测套组和自我采集方法的出现，它们提供了便利性并增加了患者的参与度。数位健康平台和远端医疗服务的整合进一步推动了病人参与并改善了后续护理。预计照护现场诊断的进步和人工智慧主导的诊断演算法的使用将提高测试的准确性和解释能力。 HPV 检测的应用范围也将扩大，不再局限于子宫颈癌筛检，而是扩展到头颈癌诊断应用，这也将为市场带来益处。战略伙伴关係、研发投资以及针对不同人群的客製化检测解决方案有望成为充分发挥市场潜力和满足未满足的临床需求的关键。

本报告研究了全球人类乳突病毒 (HPV) 检测市场，并对市场动态进行了详细分析，包括成长动力、趋势、机会和挑战。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 任务
    • 主要趋势
  • 宏观经济因素
    • 全球产业展望
    • 全球GDP成长前景
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值考虑

  • 监管格局
  • 产品采用分析
  • 价值链分析
  • 重大交易及合併
  • PESTLE分析
  • 波特五力分析

4. 全球人类乳突病毒（HPV）检测市场展望

  • 主要亮点
    • 市场规模及与前一年同期比较
    • 绝对的商机
  • 市场规模分析与预测
    • 市场规模表现分析（2019-2024）
    • 当前市场规模分析与预测（2025-2032）
  • 全球人类乳突病毒（HPV）检测市场展望：产品
    • 简介/主要发现
    • 市场规模绩效分析：依产品（2019-2024 年）
    • 目前市场规模分析及产品预测（2025-2032）
    • 市场吸引力分析：产品
  • 全球人类乳突病毒（HPV）检测市场展望：应用
    • 简介/主要发现
    • 市场规模绩效分析：按应用（2019-2024）
    • 目前市场规模分析及应用预测（2025-2032）
    • 市场吸引力分析：应用
  • 全球人类乳突病毒 (HPV) 检测市场展望：最终用户
    • 简介/主要发现
    • 按最终用户分類的市场规模绩效分析（2019-2024 年）
    • 目前市场规模分析及最终用户预测（2025-2032）
    • 市场吸引力分析：最终用户

5. 全球人类乳突病毒（HPV）检测市场（按地区）展望

  • 主要亮点
  • 市场规模绩效分析：按地区（2019-2024）
  • 目前市场规模分析及各地区预测（2025-2032）
    • 北美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美人类乳突病毒（HPV）检测市场展望

7. 欧洲人类乳突病毒（HPV）检测市场展望

8. 东亚人类乳突病毒（HPV）检测市场展望

9. 南亚和大洋洲人类乳突病毒（HPV）检测市场展望

10. 拉丁美洲人类乳突病毒（HPV）检测市场展望

11. 中东与非洲人乳头瘤病毒（HPV）检测市场展望

第十二章竞争格局

  • 市场占有率分析（2025年）
  • 市场结构
    • 竞争强度图：按市场
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • F. Hoffmann-La Roche Ltd.
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Hologic Inc.
    • Cepheid Inc.
    • Seegene Inc.
    • Takara Bio Inc.
    • DaAn Gene Co., Ltd. of Sun Yat-Sen University
    • Promega Corporation
    • Greiner Bio-One International GmbH (Greiner Holding AG)
    • Enzo Biochem Inc.
    • Norgen Biotek Corp.
    • DiagCor Bioscience Inc Ltd
    • Hybribio Limited
    • Zytovision GmbH
    • Arbor Vita Corporation
    • Medical & Biological Laboratories Co., Ltd
    • Fujirebio Diagnostics, Inc.

第十三章 附录

简介目录
Product Code: PMRREP11737

Persistence Market Research has recently released a comprehensive report on the worldwide market for Human Papillomavirus (HPV) testing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global HPV testing market from 2025 to 2032.

Key Insights:

  • HPV Testing Market Size (2025E): US$ 1,400 Mn
  • Projected Market Value (2032F): US$ 2,816.3 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032):10.5%

HPV Testing Market - Report Scope:

HPV testing is a critical component of cervical cancer screening and prevention programs. These tests detect the presence of high-risk HPV strains associated with the development of cervical cancer. The market caters to hospitals, diagnostic laboratories, and clinics, offering both DNA-based and mRNA-based testing options through various platforms including PCR, hybrid capture, and next-generation sequencing (NGS). The growing awareness about HPV and its link to cervical cancer, coupled with government initiatives promoting routine screening, is significantly propelling market growth. Rising demand for early diagnosis, expanding healthcare infrastructure in emerging regions, and the integration of HPV testing into national screening guidelines further boost market expansion.

Market Growth Drivers:

The global HPV testing market is primarily driven by the increasing prevalence of HPV infections and the rising incidence of cervical cancer worldwide. Favorable government policies and awareness campaigns advocating for routine screening and early detection have improved patient compliance and screening rates. Technological advancements such as the development of self-sampling kits, liquid-based cytology, and high-sensitivity molecular diagnostics are revolutionizing the HPV testing landscape, offering better accuracy and convenience. Furthermore, the growing focus on women's health, especially in low- and middle-income countries, is generating demand for affordable and accessible HPV screening tools. Collaborations between public health organizations and diagnostic companies are also playing a pivotal role in expanding the reach of HPV testing services.

Market Restraints:

Despite positive market momentum, several challenges persist in the HPV testing landscape. High test costs, particularly in developing economies, remain a significant barrier to widespread adoption. Limited access to advanced diagnostic tools and underdeveloped healthcare infrastructure in rural and underserved areas further hamper market penetration. Additionally, cultural barriers, stigma associated with sexual health, and lack of awareness in certain regions hinder patient participation in screening programs. Regulatory hurdles and delays in the approval of new diagnostic technologies also pose challenges for manufacturers and healthcare providers alike. Addressing these issues through education, public health investment, and innovative delivery models is crucial for sustainable market growth.

Market Opportunities:

The HPV testing market presents significant opportunities, particularly with the emergence of home-based testing kits and self-sampling methods that increase convenience and patient participation. Integration of digital health platforms and telemedicine services is further facilitating patient engagement and improving follow-up care. Advances in point-of-care diagnostics and the use of AI-driven diagnostic algorithms are expected to enhance test accuracy and interpretation. The market also stands to benefit from the expansion of HPV testing beyond cervical cancer screening, including applications in head and neck cancer diagnostics. Strategic partnerships, investments in R&D, and customized testing solutions for diverse population groups will be key to unlocking the full market potential and addressing unmet clinical needs.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the HPV testing market globally?
  • Which testing technologies and platforms are gaining traction across various regions?
  • How are innovations such as self-sampling and AI impacting the HPV diagnostics field?
  • Who are the key players in the HPV testing market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future opportunities in the global HPV testing landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global HPV testing market, including QIAGEN N.V., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, and Hologic, Inc., are focused on innovation, geographic expansion, and product portfolio diversification. These companies are investing heavily in the development of high-throughput, user-friendly testing platforms that meet international screening guidelines. Collaborations with national health programs, NGOs, and global health organizations enable these players to enhance accessibility in low-resource settings. Mergers and acquisitions, strategic licensing agreements, and regional distribution partnerships also help strengthen market presence. Companies are increasingly emphasizing awareness-building campaigns and educational initiatives to drive demand and improve health outcomes related to HPV-associated diseases.

Key Companies Profiled:

  • QIAGEN N.V.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Seegene, Inc.
  • Arbor Vita Corporation
  • bioMerieux SA
  • Thermo Fisher Scientific, Inc.
  • Cepheid (a Danaher Company)
  • NURX, Inc.

Human Papillomavirus (HPV) Testing Market Segmentation

By Product

  • DNA-based Test
  • RNA-based Test

By Application

  • Molecular Diagnostics
  • Research Use

By End User

  • Hospitals
  • Clinics
  • Diagnostics Centers
  • Research Institutes

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Human Papillomavirus Testing Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Human Papillomavirus Testing Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Human Papillomavirus Testing Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. DNA-based Test
      • 4.3.3.2. RNA-based Test
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Human Papillomavirus Testing Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Molecular Diagnostics
      • 4.4.3.2. Research Use
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Human Papillomavirus Testing Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Clinics
      • 4.5.3.3. Diagnostic Centers
      • 4.5.3.4. Research Institutes
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Human Papillomavirus Testing Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Human Papillomavirus Testing Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. DNA-based Test
    • 6.4.2. RNA-based Test
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Molecular Diagnostics
    • 6.5.2. Research Use
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Clinics
    • 6.6.3. Diagnostic Centers
    • 6.6.4. Research Institutes
  • 6.7. Market Attractiveness Analysis

7. Europe Human Papillomavirus Testing Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. DNA-based Test
    • 7.4.2. RNA-based Test
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Molecular Diagnostics
    • 7.5.2. Research Use
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Clinics
    • 7.6.3. Diagnostic Centers
    • 7.6.4. Research Institutes
  • 7.7. Market Attractiveness Analysis

8. East Asia Human Papillomavirus Testing Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. DNA-based Test
    • 8.4.2. RNA-based Test
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Molecular Diagnostics
    • 8.5.2. Research Use
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Clinics
    • 8.6.3. Diagnostic Centers
    • 8.6.4. Research Institutes
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Human Papillomavirus Testing Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. DNA-based Test
    • 9.4.2. RNA-based Test
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Molecular Diagnostics
    • 9.5.2. Research Use
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Clinics
    • 9.6.3. Diagnostic Centers
    • 9.6.4. Research Institutes
  • 9.7. Market Attractiveness Analysis

10. Latin America Human Papillomavirus Testing Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. DNA-based Test
    • 10.4.2. RNA-based Test
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Molecular Diagnostics
    • 10.5.2. Research Use
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Clinics
    • 10.6.3. Diagnostic Centers
    • 10.6.4. Research Institutes
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Human Papillomavirus Testing Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. DNA-based Test
    • 11.4.2. RNA-based Test
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Molecular Diagnostics
    • 11.5.2. Research Use
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Clinics
    • 11.6.3. Diagnostic Centers
    • 11.6.4. Research Institutes
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. F. Hoffmann-La Roche Ltd.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Agilent Technologies, Inc.
    • 12.3.3. Becton, Dickinson and Company
    • 12.3.4. Qiagen N.V.
    • 12.3.5. Thermo Fisher Scientific Inc.
    • 12.3.6. Abbott Laboratories
    • 12.3.7. Hologic Inc.
    • 12.3.8. Cepheid Inc.
    • 12.3.9. Seegene Inc.
    • 12.3.10. Takara Bio Inc.
    • 12.3.11. DaAn Gene Co., Ltd. of Sun Yat-Sen University
    • 12.3.12. Promega Corporation
    • 12.3.13. Greiner Bio-One International GmbH (Greiner Holding AG)
    • 12.3.14. Enzo Biochem Inc.
    • 12.3.15. Norgen Biotek Corp.
    • 12.3.16. DiagCor Bioscience Inc Ltd
    • 12.3.17. Hybribio Limited
    • 12.3.18. Zytovision GmbH
    • 12.3.19. Arbor Vita Corporation
    • 12.3.20. Medical & Biological Laboratories Co., Ltd
    • 12.3.21. Fujirebio Diagnostics, Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations